Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | CA1 | P00915 | 8/20 | 0.56 |
| ▸ | CA2 | P00918 | 8/20 | 0.56 |
| ▸ | CA9 | Q16790 | 8/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 5/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | TYMS | P04818 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28927348 | 0.79 | LMNA (0.76) | LMNAALDH1A1MAPK1THRBTSHR | |
| SCHEMBL11864268 | 0.78 | TERT (0.39) | LMNAALDH1A1MAPK1THRBTSHR | |
| SCHEMBL11864276 | 0.78 | TERT (0.39) | LMNAALDH1A1MAPK1THRBTSHR | |
| SCHEMBL681530 | 0.77 | LMNA (0.73) | LMNAALDH1A1MAPK1THRBTSHR | |
| Metronidazole SCHEMBL9460595 | 0.77 | LMNA (0.94) | LMNAALDH1A1MAPK1THRBTSHR | |
| Metronidazole SCHEMBL21293782 | 0.77 | LMNA (0.94) | LMNAALDH1A1MAPK1THRBTSHR | |
| Metronidazole SCHEMBL29168722 | 0.77 | LMNA (0.94) | LMNAALDH1A1MAPK1THRBTSHR | |
| Metronidazole SCHEMBL9455119 | 0.76 | LMNA (1.00) | LMNAALDH1A1MAPK1THRBTSHR | |
| SCHEMBL4273201 | 0.76 | LMNA (0.71) | LMNAALDH1A1MAPK1THRBTSHR | |
| Metronidazole SCHEMBL23042 | 0.76 | LMNA (1.00) | LMNAALDH1A1MAPK1THRBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250222066-A1 | COMPOSITIONS AND METHODS OF TREATING, PREVENTING OR INHIBITING A FACULTATIVE ANAEROBE INFECTION | UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2025-07-10 | — | — | US | claimed |
| EP-4547023-A2 | COMPOSITIONS AND METHODS OF TREATING, PREVENTING OR INHIBITING A FACULTATIVE ANAEROBE INFECTION | University of Utah Research Foundation (US) | 2025-05-07 | — | — | EP | claimed |
| US-20250032455-A1 | NITROIMIDAZOLE FORMULATIONS | IRP Health Pty Ltd (AU) | 2025-01-30 | — | — | US | claimed |
| US-12171748-B2 | Nitroimidazole formulations | IRP Health Pty Ltd (AU) | 2024-12-24 | — | — | US | claimed |
| WO-2024085926-A2 | COMPOSITIONS AND METHODS OF TREATING, PREVENTING OR INHIBITING A FACULTATIVE ANAEROBE INFECTION | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2024-04-25 | — | — | WO | claimed |
| US-20210220335-A1 | NITROIMIDAZOLE FORMULATIONS | IRP Health Pty Ltd (AU) | 2021-07-22 | — | — | US | claimed |
| EP-3810137-A1 | NITROIMIDAZOLE FORMULATIONS | IRP Health Pty Ltd (AU) | 2021-04-28 | — | — | EP | claimed |
| WO-2019227149-A1 | NITROIMIDAZOLE FORMULATIONS | IRP Health Pty Ltd (AU) | 2019-12-05 | — | — | WO | claimed |
| US-20180214459-A1 | LIQUID POLYMER DELIVERY SYSTEM FOR EXTENDED ADMINISTRATION OF DRUGS | WELLS FARGO BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT | 2018-08-02 | — | — | US | claimed |
| EP-3331495-A1 | LIQUID POLYMER DELIVERY SYSTEM FOR EXTENDED ADMINISTRATION OF DRUGS | Tolmar International Limited (IE) | 2018-06-13 | — | — | EP | claimed |
| US-20090197896-A1 | Methods and compositions for increasing solubility of azole drug compounds that are poorly soluble in water | JPMORGAN CHASE BANK, N.A. | 2009-08-06 | — | — | US | claimed |
| WO-2005058282-A1 | DOUBLE PELLET FORMULATION OF PROTON PUMP INHIBITORS AND CLARITHROMYCIN FOR THE TREATMENT OF GASTROINTESTINAL ULCER, AND METHOD FOR PRODUCING THE SAME | KOREA UNITED PHARM, INC (KR) | 2005-06-30 | — | — | WO | claimed |
| CN-1147292-C | Double capsule for the administration of active principles in multiple therepies | ������ҩ������˾ | 2004-04-28 | — | — | CN | claimed |
| EP-1037614-B1 | A DOUBLE CAPSULE FOR THE ADMINISTRATION OF ACTIVE PRINCIPLES IN MULTIPLE THERAPIES | AXCAN PHARMA INC (CA) | 2003-11-26 | — | — | EP | claimed |
| US-6350468-B1 | ORALLY ADMINISTERING TO MAMMAL DOSAGE FORM COMPRISING INTERNAL CAPSULE COMPRISING ANTIBIOTIC PLACED INSIDE EXTERNAL CAPSULE COMPRISING SOLUBLE BISMUTH SALT AND SECOND ANTIBIOTIC; TRIPLE THERAPY AGAINST MICROORGANISM HELICOBACTER PYLORI | AXCAN PHARMA INC. (CA) | 2002-02-26 | — | — | US | claimed |
| CN-1285741-A | Double-layer capsule for administering active ingredients in combination therapy | AXCAN PHARMA INC (CA) | 2001-02-28 | — | — | CN | claimed |
| EP-1037614-A2 | A DOUBLE CAPSULE FOR THE ADMINISTRATION OF ACTIVE PRINCIPLES IN MULTIPLE THERAPIES | Axcan Pharma Inc. (CA) | 2000-09-27 | — | — | EP | claimed |
| WO-1999030693-A2 | A DOUBLE CAPSULE FOR THE ADMINISTRATION OF ACTIVE PRINCIPLES IN MULTIPLE THERAPIES | AXCAN PHARMA INC. (CA) | 1999-06-24 | — | — | WO | claimed |
| WO-1999012548-A1 | TREATMENT OF INFLAMMATORY CONDITIONS | THERAMARK LIMITED (GB) | 1999-03-18 | — | — | WO | claimed |
| WO-1999012547-A1 | TREATMENT OF INFLAMMATORY CONDITIONS | THERAMARK LIMITED (GB) | 1999-03-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210220335-A1 | NITROIMIDAZOLE FORMULATIONS | PHB1, COX5B, CYP3A5 | LMNA 3271/4885ALDH1A1 3471/4885MAPK1 3643/4885 |
| US-12171748-B2 | Nitroimidazole formulations | PHB1, COX5B, CYP3A5 | LMNA 3271/4885ALDH1A1 3471/4885MAPK1 3643/4885 |
| US-20180214459-A1 | LIQUID POLYMER DELIVERY SYSTEM FOR EXTENDED ADMINISTRATION OF DRUGS | VEGFA, HACD3, HACD2 | LMNA 856/4885ALDH1A1 929/4885MAPK1 2410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.